TY - JOUR
T1 - Association of HIV status with sexual function in women aged 45–60 in England
T2 - results from two national surveys
AU - Toorabally, Nasreen
AU - Mercer, Catherine H.
AU - Mitchell, Kirstin R.
AU - Blell, Mwenza
AU - Burns, Fiona
AU - Gilson, Richard
AU - McGregor-Read, Janine
AU - Allan, Sris
AU - De Ruiter, Annemiek
AU - Dhairyawan, Rageshri
AU - Fox, Julie
AU - Gilleece, Yvonne
AU - Jones, Rachael
AU - Mackie, Nicola
AU - Obeyesekera, Sharmin
AU - Post, Frank
AU - Reeves, Iain
AU - Rosenvinge, Melanie
AU - Ross, Jonathan
AU - Sarner, Liat
AU - Sullivan, Ann
AU - Tariq, Anjum
AU - Ustianowski, Andrew
AU - Sabin, Caroline A.
AU - Tariq, Shema
N1 - Funding Information:
ADR is a full time employee of ViiV Healthcare. AU has received speaker and advisory board fees from: Abbvie, Gilead, Janssen, MSD, ViiV Healthcare; research grants from: Abbvie, Gilead; and has participated in research programmes for Abbvie, Gilead, Janssen-Cilag, MSD, and ViiV Healthcare. CS has received funding for membership of Data Safety and Monitoring Boards, Advisory Boards, speaker panels and for preparation of educational materials from Gilead Sciences, ViiV Healthcare and Janssen-Cilag. FB has received consultancy fees and conference support from Gilead Sciences. FP reports grants to King’s College Hospital NHS Foundation Trust from ViiV Healthcare and Gilead Sciences, and personal fees from Gilead Sciences, Janssen-Cilag, GlaxoSmithKline/ViiV Healthcare, and Merck. JR reports personal fees from GSK Pharma, Hologic Diagnostics and Janssen Pharma, as well as ownership of shares in GSK Pharma and AstraZeneca Pharma. RD has received educational grants from Gilead Sciences and MSD, and consultation fees from Gilead Sciences. RJ has received educational grants and personal fees from Gilead Sciences, MSD, Janssen-Cilag, Abbvie and ViiV Healthcare. ST has previously received a travel bursary funded by Janssen-Cilag through the British HIV Association, and speaker honoraria and funding for preparation of educational materials from Gilead Sciences. YG has received payment for medical education meetings and advisory boards from ViiV Healthcare, Gilead Sciences and MSD. ST, FB and CS are members of the steering group of SWIFT, a networking group for people involved in research in HIV and women, funded by Bristol Myers Squibb. All authors reporting funding from pharmaceutical companies confirm that this is outside the submitted work. For the remaining authors no COI were declared.
Funding Information:
The PRIME Study was funded by the National Institute for Health Research (NIHR) in the form of a postdoctoral fellowship to ST [grant number PDF-2014-07-071]. Natsal-3 was supported by grants from the Medical Research Council [grant number G0701757] and the Wellcome Trust [grant number 084840], with contributions from the Economic and Social Research Council and Department of Health. Since September 2015, KM has been supported by the United Kingdom Medical Research Council [grant number MC_UU_12017/11], and Scottish Government Chief Scientist Office [grant number SPHSU11]. Since March 2018, ST has received salary support through a UCL/Wellcome Institutional Strategic Support Fund Flexible Support Awards (grant number 204841/Z/16/Z).
Publisher Copyright:
© 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/3/3
Y1 - 2020/3/3
KW - HIV
KW - menopause
KW - sexual function
KW - women
UR - http://www.scopus.com/inward/record.url?scp=85070921770&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070921770&partnerID=8YFLogxK
U2 - 10.1080/09540121.2019.1653436
DO - 10.1080/09540121.2019.1653436
M3 - Article
C2 - 31411046
AN - SCOPUS:85070921770
SN - 0954-0121
VL - 32
SP - 286
EP - 295
JO - AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV
JF - AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV
IS - 3
ER -